Cargando…

A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre

The increased use of immune checkpoint inhibitors across cancer programs has created the need for standardized patient assessment, education, monitoring, and management of immune-related adverse events (irAEs). At William Osler Health System in Brampton, Ontario, a practical step-wise approach detai...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheema, Parneet K., Iafolla, Marco A. J., Nematollahi, Massey, Berco, FeRevelyn, Kaushik, Deepanjali, Matthews, Priscilla, Raskin, William R., Perdrizet, Kirstin A., Dudani, Shaan, Husain, Juhi, Balcewicz, Margaret, Kuruvilla, Philip G., Reingold, Stephen M., Conter, Henry J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870472/
https://www.ncbi.nlm.nih.gov/pubmed/35200573
http://dx.doi.org/10.3390/curroncol29020074
_version_ 1784656759188619264
author Cheema, Parneet K.
Iafolla, Marco A. J.
Nematollahi, Massey
Berco, FeRevelyn
Kaushik, Deepanjali
Matthews, Priscilla
Raskin, William R.
Perdrizet, Kirstin A.
Dudani, Shaan
Husain, Juhi
Balcewicz, Margaret
Kuruvilla, Philip G.
Reingold, Stephen M.
Conter, Henry J.
author_facet Cheema, Parneet K.
Iafolla, Marco A. J.
Nematollahi, Massey
Berco, FeRevelyn
Kaushik, Deepanjali
Matthews, Priscilla
Raskin, William R.
Perdrizet, Kirstin A.
Dudani, Shaan
Husain, Juhi
Balcewicz, Margaret
Kuruvilla, Philip G.
Reingold, Stephen M.
Conter, Henry J.
author_sort Cheema, Parneet K.
collection PubMed
description The increased use of immune checkpoint inhibitors across cancer programs has created the need for standardized patient assessment, education, monitoring, and management of immune-related adverse events (irAEs). At William Osler Health System in Brampton, Ontario, a practical step-wise approach detailing the implementation of cancer immunotherapy in routine practice was developed. The approach focuses on four key steps: (1) identification of patient educators; (2) development of patient education materials; (3) development of patient monitoring tools; (4) involvement and education of multidisciplinary teams. Here, we provide an in-depth description of what was included in each step and how we integrated the different elements of the program. For each step, resources, tools, and materials that may be useful for patients, healthcare providers, and multidisciplinary teams were developed or modified based on existing materials. At our centre, the program led to improved patient comprehension of irAEs, the ability to act on symptoms (patient self-efficacy), and low rates of emergency room visits at first presentation for irAEs. We recognize that centres may need to tailor the approaches to their institutional policies and encourage centres to adapt and modify the forms and tools according to their needs and requirements.
format Online
Article
Text
id pubmed-8870472
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88704722022-02-25 A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre Cheema, Parneet K. Iafolla, Marco A. J. Nematollahi, Massey Berco, FeRevelyn Kaushik, Deepanjali Matthews, Priscilla Raskin, William R. Perdrizet, Kirstin A. Dudani, Shaan Husain, Juhi Balcewicz, Margaret Kuruvilla, Philip G. Reingold, Stephen M. Conter, Henry J. Curr Oncol Guidelines The increased use of immune checkpoint inhibitors across cancer programs has created the need for standardized patient assessment, education, monitoring, and management of immune-related adverse events (irAEs). At William Osler Health System in Brampton, Ontario, a practical step-wise approach detailing the implementation of cancer immunotherapy in routine practice was developed. The approach focuses on four key steps: (1) identification of patient educators; (2) development of patient education materials; (3) development of patient monitoring tools; (4) involvement and education of multidisciplinary teams. Here, we provide an in-depth description of what was included in each step and how we integrated the different elements of the program. For each step, resources, tools, and materials that may be useful for patients, healthcare providers, and multidisciplinary teams were developed or modified based on existing materials. At our centre, the program led to improved patient comprehension of irAEs, the ability to act on symptoms (patient self-efficacy), and low rates of emergency room visits at first presentation for irAEs. We recognize that centres may need to tailor the approaches to their institutional policies and encourage centres to adapt and modify the forms and tools according to their needs and requirements. MDPI 2022-02-04 /pmc/articles/PMC8870472/ /pubmed/35200573 http://dx.doi.org/10.3390/curroncol29020074 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Guidelines
Cheema, Parneet K.
Iafolla, Marco A. J.
Nematollahi, Massey
Berco, FeRevelyn
Kaushik, Deepanjali
Matthews, Priscilla
Raskin, William R.
Perdrizet, Kirstin A.
Dudani, Shaan
Husain, Juhi
Balcewicz, Margaret
Kuruvilla, Philip G.
Reingold, Stephen M.
Conter, Henry J.
A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre
title A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre
title_full A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre
title_fullStr A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre
title_full_unstemmed A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre
title_short A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre
title_sort guide to implementing immune checkpoint inhibitors within a cancer program: experience from a large canadian community centre
topic Guidelines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870472/
https://www.ncbi.nlm.nih.gov/pubmed/35200573
http://dx.doi.org/10.3390/curroncol29020074
work_keys_str_mv AT cheemaparneetk aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT iafollamarcoaj aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT nematollahimassey aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT bercoferevelyn aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT kaushikdeepanjali aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT matthewspriscilla aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT raskinwilliamr aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT perdrizetkirstina aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT dudanishaan aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT husainjuhi aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT balcewiczmargaret aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT kuruvillaphilipg aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT reingoldstephenm aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT conterhenryj aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT cheemaparneetk guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT iafollamarcoaj guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT nematollahimassey guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT bercoferevelyn guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT kaushikdeepanjali guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT matthewspriscilla guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT raskinwilliamr guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT perdrizetkirstina guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT dudanishaan guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT husainjuhi guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT balcewiczmargaret guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT kuruvillaphilipg guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT reingoldstephenm guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre
AT conterhenryj guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre